Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Verona – page 6

434 clinical trials in Verona, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Verona at a glance
434
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

434 trials in Verona

Open in trial search

B-cell type acute leukaemia

Recruiting

Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

A study to test if empasiprubart can improve function and is safe for adults with chronic inflammatory demyelinating polyneuropathy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Adenocarcinoma pancreas

Recruiting

A Study of Olaparib Maintenance Treatment for Patients with Metastatic Pancreatic Cancer That Responded to First-Line Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:Universita' Degli Studi Di Verona

Narcolepsy+1

Recruiting

Long-term Safety Study of ORX750 for Patients with Narcolepsy and Idiopathic Hypersomnia Who Completed a Previous ORX750 Trial

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ORX750
  • Sponsor:Centessa Pharmaceuticals UK Limited

A Study of SAB-142 to Slow the Progression of Type 1 Diabetes in Adults and Children Recently Diagnosed with the Disease

Recruiting
Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Sodium Chloride
  • Sponsor:Sab Biotherapeutics Inc.

Non-small cell lung cancer

Recruiting

Testing zongertinib compared to standard treatment in patients with early-stage non-small cell lung cancer with HER2 mutations after surgery

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Hormone-dependent prostate cancer

Recruiting

A study testing tulmimetostat with darolutamide or abiraterone in patients with metastatic hormone-sensitive prostate cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Pancreatic carcinoma metastatic+1

Recruiting

A Study of BMS-986504 Combined with Nab-Paclitaxel and Gemcitabine for Patients with Untreated Metastatic Pancreatic Cancer with MTAP Gene Deletion

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Allogenic stem cell transplantation

Recruiting

Testing Stem Cell Transplant Methods and Medications Including Ruxolitinib and Blinatumomab for Children and Young Adults with Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Ospedale Pediatrico Bambino Gesu

Non-small cell lung cancer

Recruiting

A Study Comparing PF-08046054 to Docetaxel in Adults with Previously Treated PD-L1 Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Pfizer Inc.

Diabetes mellitus

Recruiting

A Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Teplizumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Clear cell renal cell carcinoma

Recruiting

A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AB521
  • Sponsor:Arcus Biosciences Inc.

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Verona

What the registry says about research in the country

01 Neurological Disorders

Innovative research focusing on acute ischemic stroke treatment and neurological conditions including narcolepsy and Dravet Syndrome. Studies evaluate new therapeutic approaches for improving patient outcomes and managing symptoms.

  • Stroke Treatment Optimization
  • Sleep Disorders Management
  • Seizure Control

Multiple trials exploring novel medications and treatment combinations for better patient care.

02 Oncology Research

Comprehensive studies targeting various cancers including gastric cancer, Merkel cell carcinoma, and metastatic colorectal cancer. Research focuses on innovative treatment combinations and targeted therapies.

  • Advanced Solid Tumors
  • Hematological Malignancies
  • Immunotherapy Approaches

Trials investigating novel drug combinations and personalized treatment strategies.

03 Autoimmune Conditions

Clinical investigations into Sjögren's Syndrome, systemic sclerosis, and other autoimmune disorders. Studies evaluate new biological treatments and their long-term effectiveness.

  • Connective Tissue Disorders
  • Chronic Inflammatory Conditions
  • Novel Therapeutic Approaches

Research focusing on improving quality of life and disease management for patients.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.